Roivant Sciences (NASDAQ:ROIV) Insider Sells $653,458.70 in Stock

Posted by Francis Steltz on Aug 21st, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) insider Mayukh Sukhatme sold 17,519 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $37.30, for a total transaction of $653,458.70. Following the sale, the insider owned 18,630,739 shares in the company, valued at $694,926,564.70. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88.
On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The shares were sold at an average price of $37.17, for a total transaction of $6,426,655.83.
On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71.
On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75.
On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total transaction of $5,029,879.66.

Roivant Sciences Price Performance

Roivant Sciences stock traded down $0.54 during mid-day trading on Friday, reaching $36.30. The company had a trading volume of 6,185,493 shares, compared to its average volume of 5,631,176. Roivant Sciences Ltd. has a 1 year low of $11.60 and a 1 year high of $37.97. The company has a market capitalization of $26.22 billion, a P/E ratio of -68.49 and a beta of 1.12. The stock’s 50-day simple moving average is $34.61 and its 200-day simple moving average is $30.43.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. On average, equities analysts forecast that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of ROIV. Fifth Third Bancorp lifted its position in shares of Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after purchasing an additional 376 shares during the last quarter. Bessemer Group Inc. increased its holdings in Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after buying an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its holdings in Roivant Sciences by 4.6% in the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after buying an additional 445 shares during the last quarter. Versant Capital Management Inc raised its stake in Roivant Sciences by 13.9% during the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock valued at $141,000 after buying an additional 487 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund raised its stake in Roivant Sciences by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after buying an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

ROIV has been the subject of several research reports. Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Leerink Partners set a $42.00 price target on Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday. Finally, Guggenheim boosted their price objective on shares of Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Get Our Latest Stock Report on ROIV

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.